1. Home
  2. INTS vs LGL Comparison

INTS vs LGL Comparison

Compare INTS & LGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • LGL
  • Stock Information
  • Founded
  • INTS 2012
  • LGL 1917
  • Country
  • INTS United States
  • LGL United States
  • Employees
  • INTS N/A
  • LGL N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • LGL Industrial Machinery/Components
  • Sector
  • INTS Health Care
  • LGL Technology
  • Exchange
  • INTS Nasdaq
  • LGL Nasdaq
  • Market Cap
  • INTS 33.4M
  • LGL 31.5M
  • IPO Year
  • INTS 2023
  • LGL N/A
  • Fundamental
  • Price
  • INTS $2.11
  • LGL $6.67
  • Analyst Decision
  • INTS Strong Buy
  • LGL
  • Analyst Count
  • INTS 3
  • LGL 0
  • Target Price
  • INTS $8.50
  • LGL N/A
  • AVG Volume (30 Days)
  • INTS 28.4K
  • LGL 3.7K
  • Earning Date
  • INTS 03-13-2025
  • LGL 03-31-2025
  • Dividend Yield
  • INTS N/A
  • LGL N/A
  • EPS Growth
  • INTS N/A
  • LGL 66.76
  • EPS
  • INTS N/A
  • LGL 0.07
  • Revenue
  • INTS N/A
  • LGL $4,130,000.00
  • Revenue This Year
  • INTS N/A
  • LGL N/A
  • Revenue Next Year
  • INTS N/A
  • LGL N/A
  • P/E Ratio
  • INTS N/A
  • LGL $98.09
  • Revenue Growth
  • INTS N/A
  • LGL 26.49
  • 52 Week Low
  • INTS $1.50
  • LGL $4.86
  • 52 Week High
  • INTS $5.94
  • LGL $7.35
  • Technical
  • Relative Strength Index (RSI)
  • INTS 41.98
  • LGL 51.07
  • Support Level
  • INTS $1.84
  • LGL $6.50
  • Resistance Level
  • INTS $2.53
  • LGL $6.89
  • Average True Range (ATR)
  • INTS 0.32
  • LGL 0.25
  • MACD
  • INTS -0.02
  • LGL -0.03
  • Stochastic Oscillator
  • INTS 37.50
  • LGL 56.00

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

About LGL LGL Group Inc. (The)

LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.

Share on Social Networks: